Market Spotlight: Glioblastoma
Market Spotlight: Glioblastoma
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2017, there were approximately 70,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 87,100 incident cases by 2026.
- It is estimated that the majority of diagnosed cases were in males in 2017.
- The incidence of glioblastoma is highest among older individuals aged 75–84 years. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for GBM.
- The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II. Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes. • High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase II trial results for Opdivo and GDC0084, an expected program partnership or acquisition for ICT-107, topline Phase III trial results for DCVax-Brain, Toca 511, and Trans Sodium Crocetinate (TSC), and topline Phase Ib/IIa trial results for INO-5401.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 40.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 39 licensing and asset acquisition deals involving glioblastoma drugs during 2014–19. The largest deal during the period was the $548m licensing agreement between I-Mab Biopharma and Genexine in 2017, to develop and commercialize a proprietary long-acting immuno-oncology drug (HyLeukin) in the Greater China territories.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of glioblastoma clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 78 trials.
- Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, followed by Roche and Novartis
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Risk factors
10 Radiation therapy
10 Tumor-treating fields (TTFs)
11 Targeted therapy
16 MARKETED DRUGS
19 PIPELINE DRUGS
38 RECENT EVENTS AND ANALYST OPINION
38 AG-881 for Glioblastoma (June 3, 2019)
39 DS-1001 for Glioblastoma (June 3, 2019)
40 Tibsovo for Glioblastoma (June 3, 2019)
42 Opdivo for Glioblastoma (May 9, 2019)
43 MDNA55 for Glioblastoma (October 31, 2018)
44 DCVax-Brain for Glioblastoma (May 29, 2018)
45 VB-111 for Glioblastoma (March 8, 2018)
48 KEY UPCOMING EVENTS
49 KEY REGULATORY EVENTS
49 Approval of SonoCloud-9 ultrasound device
50 PROBABILITY OF SUCCESS
51 LICENSING AND ASSET ACQUISITION DEALS
51 Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
51 1ST Bio, twoXAR Join Hands To Discover, Develop GBM Treatments
52 Troubled MabVax To Merge With Oncotelic
52 FUJIFILM Licenses Oncology Radiopharmaceutical To Novartis Affiliate
52 Pascal Licenses Cannabinoid-Based Cancer Therapy From U Of Washington
52 Oblato Gets GBM Candidate From Oklahoma Medical Research Foundation
54 PARENT PATENTS
56 REVENUE OPPORTUNITY
57 CLINICAL TRIAL LANDSCAPE
58 Sponsors by status
59 Sponsors by phase
60 Recent events
63 Prescription information
LIST OF FIGURES
14 Figure 1: Trends in incident cases of glioblastoma, 2017–26
19 Figure 2: Overview of pipeline drugs for glioblastoma in the US
19 Figure 3: Pipeline drugs for glioblastoma, by company
20 Figure 4: Pipeline drugs for glioblastoma, by drug type
20 Figure 5: Pipeline drugs for glioblastoma, by classification
43 Figure 6: Opdivo for Glioblastoma (May 9, 2019): Phase III – vs. Temozolomide (CheckMate 498)
44 Figure 7: MDNA55 for Glioblastoma (October 31, 2018): Phase IIb – MDNA55-05 (rGBM)
47 Figure 8: VB-111 for Glioblastoma (March 8, 2018): Phase III – GLOBE
48 Figure 9: Key upcoming events in glioblastoma
50 Figure 10: Probability of success in the glioblastoma pipeline
51 Figure 11: Licensing and asset acquisition deals in glioblastoma, 2014–19
54 Figure 12: Parent patents in glioblastoma
55 Figure 13: Parent patents in glioblastoma [continued]
57 Figure 14: Clinical trials in glioblastoma
57 Figure 15: Top 10 drugs for clinical trials in glioblastoma
58 Figure 16: Top 10 companies for clinical trials in glioblastoma
58 Figure 17: Trial locations in glioblastoma
59 Figure 18: Glioblastoma trials status
60 Figure 19: Glioblastoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of glioblastoma, 2017–26
15 Table 2: Incident cases of glioblastoma, by gender, 2017
17 Table 3: Marketed drugs for glioblastoma
22 Table 4: Pipeline drugs for glioblastoma in the US
38 Table 5: AG-881 for Glioblastoma (June 3, 2019)
39 Table 6: DS-1001 for Glioblastoma (June 3, 2019)
41 Table 7: Tibsovo for Glioblastoma (June 3, 2019)
42 Table 8: Opdivo for Glioblastoma (May 9, 2019)
43 Table 9: MDNA55 for Glioblastoma (October 31, 2018)
45 Table 10: DCVax-Brain for Glioblastoma (May 29, 2018)
46 Table 11: VB-111 for Glioblastoma (March 8, 2018)
56 Table 12: Historical global sales, by drug ($m), 2014–18
56 Table 13: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.